Drug Target Review

NOVEMBER 25, 2024

At this point, I knew that I wanted to join the biotech and pharmaceutical industry, so I moved to a small biotech company in London, where I spent three to four years learning the fundamentals of the biotech industry. Personally, I went from working in licensing and business development in big pharma straight to being a CEO.

Treatment

BioPharma Drive: Drug Pricing

JULY 8, 2025

Published July 8, 2025 Gwendolyn Wu Senior reporter post share post print email license Proteasomes are cellular machines for breaking down proteins. Multiple deals have been struck by large companies such as Roche and Novartis, suggesting pharmaceutical firms believe degraders have only begun to show their promise.

Targeted Protein Degradation

Drug Target Review

DECEMBER 9, 2024

AI is influencing all industries, but its impact will be especially strong in pharmaceuticals where it is expected to accelerate drug discovery and, in clinical settings, generate patterns and insights from vast quantities of patient data to enable more personalised treatments.As

Engineering

The Pharma Data

JUNE 24, 2025

Bayer and Tsinghua University Deepen Strategic Alliance to Advance Pharmaceutical Innovation in China Bayer and Tsinghua University (THU), two powerhouses in global pharmaceutical innovation and academic research, have announced a renewed commitment to their long-standing partnership.

Pharma R&D

BioPharma Drive: Drug Pricing

JULY 14, 2025

Published July 14, 2025 Ben Fidler Senior Editor post share post print email license Takeda reported positive results for oveporexton, a drug being developed for narcolepsy Type 1, on July 14, 2025. The drug, formerly known as TAK-861 but now called oveporexton, was evaluated in two Phase 3 studies in a main type of narcolepsy.

Drugs

The Pharma Data

JUNE 24, 2025

Rather than diluting ownership or yielding developmental control to a larger pharmaceutical partner, Revolution Medicines is leveraging this funding arrangement to maintain autonomy over its research, development, and eventual commercialization efforts. This aligns both parties’ interests toward long-term success in the market.

Clinical Development

DrugBank

JUNE 18, 2025

While these regulations protect public health, they also introduce significant challenges for pharmaceutical researchers. This means pharmaceutical companies must remain vigilant and adaptable to comply with evolving regulations. One of the most significant challenges in drug development is global regulatory variability.

Drug Development

New Drug Approvals

JUNE 11, 2025

2] Gepirone was synthesized by Bristol-Myers Squibb in 1986 and was developed and marketed by Fabre-Kramer Pharmaceuticals. [4] 5] History Gepirone was developed by Bristol-Myers Squibb in 1986, [5] but was out-licensed to Fabre-Kramer in 1993. 1] It is taken orally. [1] 1] It is taken orally. [1] American Psychiatric Pub.

FDA

New Drug Approvals

JULY 25, 2025

2] [3] Vamorolone is a novel and fully synthetic glucocorticoid developed by Santhera Pharmaceuticals. 10] Society and culture Legal status Santhera Pharmaceuticals signed an agreement with Catalyst Pharmaceuticals for the North American commercialization of vamorolone in July 2023. [20] Santhera Pharmaceuticals Holding AG.

FDA

The Pharma Data

JULY 2, 2025

Ziihera is being jointly developed by Jazz Pharmaceuticals and BeOne Medicines Ltd. under license from Zymeworks Inc. , EU, Japan, and most global markets outside of the Asia-Pacific region (excluding Japan), which remain under BeiGene’s purview. formerly BeiGene, Ltd.) the original developer.

Therapies

Drug Target Review

JULY 29, 2025

As the pharmaceutical and biotech industries continue to evolve, clinical trials become more complex, and the importance of robust financial oversight has never been clearer. Ultimately, this will help to accelerate the development of new treatments, ensuring that promising therapies make it to market in a timely and cost-effective manner.

Clinical Trials

BioPharma Drive: Drug Pricing

JUNE 11, 2025

Published June 11, 2025 Ben Fidler Senior Editor post share post print email license The FDA on June 11, 2025 approved Nuvation's Ibtrozi for ROS1-positive non-small cell lung cancer. In a research note on Wednesday, RBC Capital Markets analyst Leonid Timashev estimated peak yearly sales of the drug could reach nearly $640 million.

FDA

SugarCone Biotech

JULY 6, 2025

Finally, while there are clear front runners among the pharmaceutical companies developing targeted therapeutics for these antigens there are also emerging biotechs aggressively pursuing these targets. Each target and each therapeutic modality induces varying degrees of clinical efficacy, as well as causing toxicities.

Drug Development

Drug Patent Watch

DECEMBER 18, 2024

As a business professional in the pharmaceutical industry, understanding and implementing effective strategies for drug patent prosecution can be the difference between market domination and missed opportunities. However, because it takes so long to bring a drug to market, the effective patent life is often much shorter.

Pharmaceuticals

New Drug Approvals

APRIL 18, 2025

potassium hydroxide), and water to prepare 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine (Compound 1) or a pharmaceutically acceptable salt thereof is provided below in Scheme VII. Br), in the presence of an alkylating-step solvent (e.g.,

FDA

BioPharma Drive: Drug Pricing

JULY 10, 2025

Published July 10, 2025 Delilah Alvarado Staff Reporter post share post print email license The Food and Drug Administration on July 10, 2025, issued Moderna a full approval in children for its COVID-19 vaccine Spikevax. Kennedy Jr., who has pushed for policy changes around mRNA vaccines in particular. You can unsubscribe at anytime.

Vaccine

BioPharma Drive: Drug Pricing

JULY 10, 2025

Published July 10, 2025 Ben Fidler Senior Editor post share post print email license Soleno Therapeutics on July 10, 2025 announced preliminary sales for its new Prader-Willi Syndrome drug Vykat. This database now covers the 50 best-selling pharmaceutical products and has been updated to reflect current patent expiry expectations.

Drugs

BioPharma Drive: Drug Pricing

JULY 30, 2025

Published July 30, 2025 Ned Pagliarulo Lead Editor post share post print email license Daniel Tadevosyan via Getty Images Today, a brief rundown of news involving Madrigal Pharmaceuticals and Viridian Therapeutics, as well as updates from Apellis Pharmaceuticals, PTC Therapeutics and Arrowhead Pharmaceuticals that you may have missed.

Drugs

BioPharma Drive: Drug Pricing

JUNE 26, 2025

Published June 26, 2025 Ned Pagliarulo Lead Editor post share post print email license An Incyte researcher works in a laboratory. and sold [Karuna],” wrote RBC Capital Markets analyst Brian Abrahams, in a note to clients. On June 26, 2025, the company announced the replacement of longtime CEO Hervé Hoppenot with Bill Meury.

Therapies

Drug Patent Watch

JANUARY 8, 2025

This comprehensive guide will walk you through the intricacies of optimizing your drug patent strategy, ensuring that your innovations are safeguarded and your market position is strengthened. Types of Patents in the Pharmaceutical Industry Not all patents are created equal.

Pharmaceutical Companies

BioPharma Drive: Drug Pricing

JULY 28, 2025

Fragmented approaches – whether through retail or oversized specialty hub models, or limited alternative solutions that lack true integration – simply cannot deliver the efficiency, control, and customization that market-defining brands need. Book a demo to discover how PHIL can help your specialty-lite brands secure commercial success.

Specialty Pharmacies

The Pharma Data

JULY 2, 2025

Under Birgitte’s guidance, Genmab successfully navigated key licensing agreements, multiple strategic collaborations with leading pharmaceutical companies, and its listing on the Nasdaq Global Select Market.

Compliance

BioPharma Drive: Drug Pricing

AUGUST 11, 2025

Deep Dive Library Events Press Releases Topics Sign up Search Sign up Search Pharma Biotech FDA Clinical Trials Deals Drug Pricing Gene Therapy An article from Sponsored Regulatory uncertainty and access challenges changing go-to-market models, DTC, and DTP Published Aug. The disconnect?

Marketing

Drug Channels

APRIL 15, 2025

In todays fast-moving pharmaceutical marketplace, insight is everything. Why Professionals Choose DCI eLearning These modules were built from the ground up for pharmaceutical professionalsfrom seasoned experts to newcomers looking to understand the industry's complex web of relationships. pharmaceutical distribution.

Specialty Pharmacies

Drug Patent Watch

MAY 13, 2025

"Unlocking the Secrets to Smarter Partnerships: How One Tool is Revolutionizing the Way Pharma Companies Approach Out-Licensing and Partnering Decisions As the pharmaceutical industry continues to evolve, companies are under increasing pressure to maximize their portfolios and minimize risk.

Licensing

DrugBank

OCTOBER 4, 2024

Deal Structuring Deal structuring in pharmaceutical M&A requires a balance of financial, legal, and strategic considerations. Intellectual Property Valuation Valuing intellectual property (IP) assets is a critical component of pharmaceutical M&A, as these assets often represent a significant portion of a company's value.

Pharmaceuticals

BioPharma Drive: Drug Pricing

JULY 22, 2025

Published July 22, 2025 By BioPharma Dive staff post share post print email license Daniel Tadevosyan via Getty Images Today, a brief rundown of news involving Replimune Group and Johnson & Johnson, as well as updates from Omega Funds, iTeos Therapeutics and Roche that you may have missed. and European life sciences companies.

FDA

Drug Channels

OCTOBER 5, 2021

I am pleased to announce our new 2021–22 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors , available for purchase and immediate download. pharmaceutical distribution industry. reviews AmerisourceBergen’s entry into the European distribution market. (We Section 4.4. Section 7.4.4. Section 6.1.5.

Pharmaceuticals

Drug Patent Watch

FEBRUARY 3, 2021

This article was originally published by Ioana Gherghescu and Begoña Delgado-Charro in Pharmaceutics 2021, 13(1) under a Creative Commons Attribution License. Abstract Biosimilar medicines expand the biotherapeutic market and improve….

Biosimilars

BioPharma Drive: Drug Pricing

JULY 22, 2025

Published July 22, 2025 • Updated 2 hours ago Delilah Alvarado Staff Reporter post share post print email license A sign bearing Sanofi's logo sits outside the company's U.S. JHVE Photo via Getty Images Dive Brief: French pharmaceutical giant Sanofi said Tuesday it will pay $1.15 headquarters in Bridgewater, New Jersey.

Vaccine

Drug Channels

OCTOBER 11, 2022

I am pleased to announce our new 2022–23 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors , available for purchase and immediate download. pharmaceutical distribution industry. examines how the Inflation Reduction Act could ultimately impact pharmaceutical wholesalers’ customers and business outlook.

Pharmaceuticals

The Pharma Data

JANUARY 6, 2021

CAMBRIDGE, England & WETHERBY, England–( BUSINESS WIRE )– Avacta Group plc (AIM: AVCT), the developer of innovative cancer therapies and diagnostics based on its proprietary Affimer ® and pre|CISION platforms, is pleased to announce that it has entered into a license agreement with POINT Biopharma Inc.

Licensing

The Pharma Data

DECEMBER 20, 2020

Allecra, subject to the satisfaction of terms and conditions as set forth in the Exclusive Licensing Agreement, is to receive an upfront cash payment and is eligible to receive additional development and commercial milestone payments with an overall deal value of $78 million, in addition to royalties.

Licensing

The Pharma Data

JANUARY 6, 2021

a leading global provider of immuno-oncology imaging agents, today announced it has signed a new multi-year, non-exclusive license with Pfizer Inc. ImaginAb will receive license fees and payments for manufacturing and other support. Working with leading pharmaceutical companies such as Pfizer, will help us achieve our goal.”

Licensing

The Pharma Data

JULY 18, 2021

Food and Drug Administration (FDA) granted Priority Review designation for the Biologics License Application (BLA) for their mRNA vaccine to prevent COVID-19 in individuals 16 years of age and older. The Pfizer-BioNTech COVID-19 vaccine has not been approved or licensed by the U.S. Pfizer Inc. Source link: [link].

Licensing

Drug Channels

MARCH 15, 2022

Prescription Market (press release) We’re offering special discounted pricing if you order before March 28, 2022. As always, we have updated all market and industry data with the most current information available, including our annual analyses of the market positions of the largest pharmacies, specialty pharmacies, and PBMs.

Pharmacy

The Pharma Data

JANUARY 3, 2021

03, 2021 (GLOBE NEWSWIRE) — EyePoint Pharmaceuticals, Inc. NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that Ocumension Therapeutics, a China-based ophthalmic pharmaceutical company traded on the Stock Exchange of Hong Kong (1477.HK),

Pharmaceuticals